Following a phase 1b trial, the potent and selective dual inhibitor of IRAK1 and IRAK4 received fast track designation for the treatment of patients with lower-risk myelodysplastic syndrome.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback